Gsk (GSK) Total Current Liabilities (2009 - 2026)
Gsk (GSK) posted Total Current Liabilities of $28.5 billion for Q4 2025, up 2.17% on a QoQ basis from $27.8 billion in Q4 2024, and up 2.17% year-over-year from $27.8 billion in Q4 2024.
Gsk (GSK) has 10 years of Total Current Liabilities data on file, last reported at $28.5 billion in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 2.17% year-over-year to $28.5 billion; the TTM figure through Dec 2025 stood at $28.5 billion (up 2.17% YoY), while the FY2025 annual figure was $28.5 billion, up 2.17% from the prior year.
- Total Current Liabilities improved to $28.5 billion in Q4 2025, from $27.8 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $31.9 billion in Q4 2021 and bottomed at $26.1 billion in Q4 2023.
- A 5-year average of $28.2 billion and a median of $27.8 billion in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities climbed 9.1% — and 2022, when it retreated 16.15%.
- Year by year, Total Current Liabilities stood at $31.9 billion in 2021, then retreated by 16.15% to $26.8 billion in 2022, then decreased by 2.26% to $26.1 billion in 2023, then climbed by 6.5% to $27.8 billion in 2024, then grew by 2.17% to $28.5 billion in 2025.
- The last three Total Current Liabilities figures came in at $28.5 billion (Q4 2025), $27.8 billion (Q4 2024), and $26.1 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 36.63 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 57.72 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 42.10 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 19.16 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 28.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.24 Bn |
| Dec 31, 2025 | -28.45 Bn |
| Sep 30, 2025 | -28.79 Bn |
| Jun 30, 2025 | -27.19 Bn |
| Mar 31, 2025 | -26.24 Bn |
| Dec 31, 2024 | 27.85 Bn |
| Sep 30, 2024 | -27.88 Bn |
| Jun 30, 2024 | -25.68 Bn |
| Mar 31, 2024 | -25.18 Bn |
| Dec 31, 2023 | 26.15 Bn |
| Sep 30, 2023 | -28.36 Bn |
| Jun 30, 2023 | -27.67 Bn |
| Mar 31, 2023 | -25.16 Bn |
| Dec 31, 2022 | 26.75 Bn |
| Sep 30, 2022 | -24.69 Bn |
| Jun 30, 2022 | -47.65 Bn |
| Mar 31, 2022 | -6.74 Bn |
| Dec 31, 2021 | 31.91 Bn |
| Sep 30, 2021 | -30.90 Bn |
| Jun 30, 2021 | -29.89 Bn |
| Mar 31, 2021 | -27.96 Bn |
| Dec 31, 2020 | 29.25 Bn |
| Jun 30, 2020 | -29.71 Bn |
| Mar 31, 2020 | -32.48 Bn |
| Dec 31, 2019 | 30.92 Bn |
| Sep 30, 2019 | -31.47 Bn |
| Jun 30, 2019 | -33.16 Bn |
| Mar 31, 2019 | -31.84 Bn |
| Dec 31, 2018 | 28.94 Bn |
| Sep 30, 2018 | -23.98 Bn |
| Jun 30, 2018 | -24.79 Bn |
| Mar 31, 2018 | -37.46 Bn |
| Dec 31, 2017 | 35.27 Bn |
| Sep 30, 2017 | -35.90 Bn |
| Jun 30, 2017 | -36.79 Bn |
| Mar 31, 2017 | -23.24 Bn |
| Dec 31, 2016 | 23.62 Bn |
| Sep 30, 2016 | -23.84 Bn |
| Jun 30, 2016 | -26.01 Bn |
| Mar 31, 2016 | -19.95 Bn |
| Dec 31, 2015 | -20.36 Bn |
| Sep 30, 2015 | -21.57 Bn |
| Jun 30, 2015 | -21.69 Bn |
| Mar 31, 2015 | -23.94 Bn |
| Dec 31, 2014 | -21.06 Bn |
| Sep 30, 2014 | -25.53 Bn |
| Jun 30, 2014 | -20.62 Bn |
| Mar 31, 2014 | -19.31 Bn |
| Dec 31, 2013 | -22.14 Bn |
| Sep 30, 2013 | -19.89 Bn |
| Jun 30, 2013 | -19.16 Bn |
| Mar 31, 2013 | -18.67 Bn |
| Dec 31, 2012 | 817.39 Mn |
| Sep 30, 2012 | -22.05 Bn |
| Jun 30, 2012 | -24.39 Bn |
| Mar 31, 2012 | -22.83 Bn |
| Dec 31, 2011 | 674.20 Mn |
| Sep 30, 2011 | -21.11 Bn |
| Jun 30, 2011 | -22.21 Bn |
| Mar 31, 2011 | -21.00 Bn |
| Dec 31, 2010 | -20.21 Bn |
| Sep 30, 2010 | -17.43 Bn |
| Jun 30, 2010 | -17.91 Bn |
| Mar 31, 2010 | -18.97 Bn |
| Dec 31, 2009 | -19.79 Bn |
| Sep 30, 2009 | -18.25 Bn |
| Jun 30, 2009 | -13.99 Bn |
| Mar 31, 2009 | -14.00 Bn |